drugset / Trial / NCT02360579

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579

Phase 2 Completed 220 enrolled Iovance Biotherapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.

Timeline

Start
2015-09-24
Primary completion
2024-10-24
Completion
2024-10-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor Infiltrating Lymphocytes Cell therapy

Indications